Login to Your Account

Astrazeneca spinout Entasis off and running with anti-infective portfolio

By Marie Powers
News Editor

Friday, July 17, 2015
Astrazeneca plc spinout Entasis Therapeutics Inc. has come in from the cold with a portfolio of drugs that previously resided in the pharma's anti-infectives pipeline and a fistful of cash from its erstwhile parent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription